• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Investigating Bacterial Motion for New Treatment Strategies

      Investigating Bacterial Motion for New Treatment Strategies

      Smart Sutures Sense Inflammation, Deliver Drugs, Cells

      Smart Sutures Sense Inflammation, Deliver Drugs, Cells

      siRNA as a COVID-19 Treatment

      siRNA as a COVID-19 Treatment

      Cancer Organoids Offer Insights into Treatment Outcomes

      Cancer Organoids Offer Insights into Treatment Outcomes

    • Radiology
      Implanted Ultrasound Lets Chemo Access Brain

      Implanted Ultrasound Lets Chemo Access Brain

      Wearable Ultrasound Measures Tissue Stiffness Under Skin

      Wearable Ultrasound Measures Tissue Stiffness Under Skin

      Brain Decoder Spells Out Thoughts

      Brain Decoder Spells Out Thoughts

      RF Technology for Health Monitoring: Michael Leabman, CTO of Movano Health

      RF Technology for Health Monitoring: Michael Leabman, CTO of Movano Health

    • Cardiology
      Pencil-on-Paper Wearable Sensor

      Pencil-on-Paper Wearable Sensor

      Cell Culture Chamber Mimics Mechanical States of Disease

      Cell Culture Chamber Mimics Mechanical States of Disease

      Chest Wearable Provides Key Heart Measurements

      Chest Wearable Provides Key Heart Measurements

      Vein on a Chip Includes Flexible Valves

      Vein on a Chip Includes Flexible Valves

    • Surgery
      Smart Sutures Sense Inflammation, Deliver Drugs, Cells

      Smart Sutures Sense Inflammation, Deliver Drugs, Cells

      Automated Computer Assistant for Kidney Transplant Rejection Diagnostics: Interview with Study Authors

      Automated Computer Assistant for Kidney Transplant Rejection Diagnostics: Interview with Study Authors

      Soft Robotic Electrode Enables Minimally Invasive Placement

      Soft Robotic Electrode Enables Minimally Invasive Placement

      Wound Dressing Detects Infection, Changes Color

      Wound Dressing Detects Infection, Changes Color

    • Nanomedicine
      Bottlebrush Nanoparticles Deliver Immunostimulatory Drugs

      Bottlebrush Nanoparticles Deliver Immunostimulatory Drugs

      Nanoparticles Deliver mRNA Therapy to the Lungs

      Nanoparticles Deliver mRNA Therapy to the Lungs

      Nanoparticles Get Lymphatic Vessels Pumping

      Nanoparticles Get Lymphatic Vessels Pumping

      Bottlebrush Particle for Synergistic Drug Combinations

      Bottlebrush Particle for Synergistic Drug Combinations

    • Military Medicine
      Wearable Can Take Multiple Sweat Samples

      Wearable Can Take Multiple Sweat Samples

      Wound Dressing Detects Infection, Changes Color

      Wound Dressing Detects Infection, Changes Color

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

    • Rehab
      Brain Decoder Spells Out Thoughts

      Brain Decoder Spells Out Thoughts

      Knitted Glove Massages the Hand to Treat Edema

      Knitted Glove Massages the Hand to Treat Edema

      Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

      Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

At 56.0% CAGR, Hemophilia Gene Therapy Market to Surpass US$ 780.0 Million by 2026 | Says Coherent Market Insights

August 26th, 2019 Coherent Market Insights Releases

The global hemophilia gene therapy market, by Hemophilia Type (Hemophilia A and Hemophilia B), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 00.0 million in 2017 and is projected to exhibit a CAGR of 56.0% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Hemophilia is one of the prominent genetic disorders that is characterized by the absence of clotting factors of specific type resulting in lack of coagulation after blood loss. This may result in serious health complications. Bleeding may be due to injury to external tissue or spontaneous bleeding in muscles and joints. Existing therapy offers symptomatic approach where clotting factors that are absent are provided externally on regular basis. However, there are many limitations of this approach such as toxicity, short term efficacy, high cost, and accessibility. Gene therapy offers solutions to all these limitations. Most important is the ability of the hemophilia gene therapy to address the root cause of hemophilia, which is caused due to genetic mutations of the gene that codes for the clotting factors VIII (Hemophilia A) and clotting factors IX (Hemophilia B). In gene therapy, specific gene is inserted into viral vectors (rAAV is most commonly used as vectors) and this vector-based gene is injected intravenously into hemophilic patients, which then codes for formation of coagulation factors.

Growing patient base for hemophilia

Increasing prevalence of hemophilia worldwide is expected to drive growth of the hemophilia gene therapy market. In 2016, World Federation of Hemophilia stated that 1 in 5,000 people are affected by hemophilia A and 1 in 50,000 are affected by hemophilia B. According to the National Hemophilia Foundation factsheet 2018, over 400,000 individuals were affected by hemophilia worldwide. Furthermore, according to same source, an estimated 75% of patients suffering from hemophilia have no access to treatment or receive inadequate treatment. According to the Centers for Disease Control and Prevention (CDC), the median age for diagnosis is one month for individuals with severe symptoms, 8 months for individuals with moderate hemophilia, and 36 months for people with mild hemophilia.

Strong product pipeline for hemophilia gene therapy

There are numerous pharma and biotech companies that are engaged in developing hemophilia gene therapy. Most of the companies are targeting hemophilia A, which has approximately 80% share in overall hemophilia patients. BioMarin Pharmaceuticals’ investigational gene therapy, Valoctocogene roxaparvovec for treating hemophilia A, is currently in phase III and Sangamo therapeutics’ investigational gene therapy SB – 525 is in phase I/II, which gave positive preliminary data in August 2018. In December 2018, Spark Therapeutics announced updated preliminary data for the ongoing phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A. Shire PLC’s gene therapy SHP654 for hemophilia A is currently in phase I of clinical development. It is expected that the first gene therapy would enter the market by 2022. Overall, as per database of clinicaltrial.gov, there are around 17 investigational gene therapies under development. Although hemophilia gene therapy may be accessible to only limited number of patients initially due to uniqueness of therapy, it may be widely used over the period, majorly in emerging economies in Asia Pacific and the Middle East, where coagulation factors replacement therapy has limited access.

Browse 16 Market Data Tables and 21 Figures spread through 110 Pages and in-depth TOC on “Hemophilia Gene Therapy Market – by Hemophilia Type (Hemophilia A and Hemophilia B) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)– Global forecast to 2026”

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2480

There are various steps taken by the U.S. FDA to speed up the clinical development of hemophilia gene therapy. The U.S. FDA has allotted breakthrough therapy designation to several investigational gene therapy. For instance, in 2017, the U.S. Food and Drug Administration granted breakthrough therapy designation to valoctocogene roxaparvovec of BioMarin Pharmaceuticals. Inc. Earlier in 2016, company received orphan drug designation for valoctocogene roxaparvovec. The U.S FDA also announced new draft guidelines in 2018 that provides information about the required design and other parameters for an accelerated approval approach, which would help the developers of human gene therapy (GT) products for the treatment of hemophilia A & B.

Key Takeaways of the Hemophilia Gene Therapy Market:

  • The global hemophilia gene therapy market is expected to exhibit a CAGR of 56.0% over the forecast period, owing to increasing prevalence of hemophilia worldwide, high cost and limitations with the current clotting factor replacement therapy, and high number of investigational gene therapy under clinical development stage
  • Among hemophilia type, hemophilia A segment is expected to hold dominant position in the market due to high prevalence rate amongst population worldwide
  • North America is expected to hold dominant position in the market, followed by Europe and Asia Pacific. The U.S. has high annual cost of hemophilia treatment. Current medication regimen to treat hemophilia costs around US$ 270,000 annually per patient, according to a 2015 Express Scripts report. This cost may be with gene therapy, which is comparatively sustainable.
  • Key players operating in the global hemophilia gene therapy market include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics.

Detailed Segmentation:

  • Global Hemophilia Gene Therapy Market, By Type:
    • Hemophilia A
    • Hemophilia B
  • Global Hemophilia Gene Therapy Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
  • Company Profiles
    • BioMarin Pharmaceuticals, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Market Strategies
    • Spark Therapeutics
    • Pfizer, Inc.
    • UniQure NV
    • Ultragenyx Pharmaceutical
    • Shire PLC
    • Sangamo Therapeutics
    • Freeline Therapeutics

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

Sign up and submit a press release

Sponsored

Packaging Compliance Labs (PCL) Celebrates Site Expansion in Grand Rapids, MI

Novel Approach to Assessing Lung Function Enables Improved Detection, Diagnosis and Treatment Decisions in Subject Exposed to Military Burn Pits

U.S. Patent Office Grants Additional Patent Protection For  Exoskeleton Focal-Force Angioplasty Platform

U.S. Patent Office Grants Additional Patent Protection For Exoskeleton Focal-Force Angioplasty Platform

Reliefband® State of Nausea Study Reveals More Than Three-Quarters of Americans Are Prevented from Enjoying Life As a Result of Regular Nausea

Reliefband® State of Nausea Study Reveals More Than Three-Quarters of Americans Are Prevented from Enjoying Life As a Result of Regular Nausea

New AI-Powered Voice Controls Streamline Ultrasound Imaging with All Clarius Handheld Systems

New AI-Powered Voice Controls Streamline Ultrasound Imaging with All Clarius Handheld Systems

interviews & reviews
Automated Computer Assistant for Kidney Transplant Rejection Diagnostics: Interview with Study Authors

Automated Computer Assistant for Kidney Transplant Rejection Diagnostics: Interview with Study Authors

RF Technology for Health Monitoring: Michael Leabman, CTO of Movano Health

RF Technology for Health Monitoring: Michael Leabman, CTO of Movano Health

AI’s role in Healthcare: Exclusive Interview with Catherine Estrampes, President & CEO at GE Healthcare

AI’s role in Healthcare: Exclusive Interview with Catherine Estrampes, President & CEO at GE Healthcare

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Levels Is Making Metabolism and Blood Glucose Tracking Accessible To Everyone

Levels Is Making Metabolism and Blood Glucose Tracking Accessible To Everyone

Imagene Profiles Cancer Biomarkers in Real Time

Imagene Profiles Cancer Biomarkers in Real Time

Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email